Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMPVDQ3)

Drug Name
Milademetan Drug Info
Synonyms
Milademetan; 1398568-47-2; DS-3032; MDM2 inhibitor DS-3032; R3I80TLN7S; DS-3032B; DS3032; 2,6-Anhydro-5-((((3'R,4'S,5'R)-6''-chloro-4'-(2-chloro-3-fluoro-4-pyridinyl)-1'',2''-dihydro-4,4-dimethyl-2''-oxodispiro(cyclohexane-1,2'-pyrrolidine-3',3''-(3H)indol)-5'-yl)carbonyl)amino)-3,4,5-trideoxy-L-erythro-hexonamide; L-Erythro-hexonamide, 2,6-anhydro-5-((((3'R,4'S,5'R)-6''-chloro-4'-(2-chloro-3-fluoro-4-pyridinyl)-1'',2''-dihydro-4,4-dimethyl-2''-oxodispiro(cyclohexane-1,2'-pyrrolidine-3',3''-(3H)indol)-5'-yl)carbonyl)amino)-3,4,5-trideoxy-; L-erythro-Hexonamide, 2,6-anhydro-5-[[[(3'R,4'S,5'R)-6''-chloro-4'-(2-chloro-3-fluoro-4-pyridinyl)-1'',2''-dihydro-4,4-dimethyl-2''-oxodispiro[cyclohexane-1,2'-pyrrolidine-3',3''-[3H]indol]-5'-yl]carbonyl]amino]-3,4,5-trideoxy-; MILADEMETAN [INN]; MILADEMETAN [USAN]; UNII-R3I80TLN7S; MILADEMETAN [WHO-DD]; RAIN-32; DS3032b; CHEMBL4292264; SCHEMBL12527208; GTPL12941; RYAYYVTWKAOAJF-QISPRATLSA-N; EX-A6155; YFC56847; BDBM50467678; NSC800893; AKOS040733738; DB15257; NSC-800893; MS-30758; HY-101266; CS-0021065; Q27896170; (3'R,4'S,5'R)-N-((3R,6S)-6-Carbamoyltetrahydro-2H-pyran-3-yl)-6''-chloro-4'-(2-chloro-3-fluoro-4-pyridinyl)-4,4-dimethyl-2''-oxo-1'',2''-dihydrodispiro(cyclohexane-1,2'-pyrrolidine-3',3''-indole)-5'-carboxamide; (3'R,4'S,5'R)-N-[(3R,6S)-6-carbamoyloxan-3-yl]-6''-chloro-4'-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-2''-oxo-1'',2''-dihydrodispiro[cyclohexane-1,2'-pyrrolidine-3',3''-indole]-5'-carboxamide; (3'R,4'S,5'R)-N-[(3R,6S)-6-carbamoyltetrahydro-2H-pyran-3-yl]-6''-chloro-4'-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-2''-oxo-1'',2''-dihydrodispiro[cyclohexane-1,2'-pyrrolidine-3',3''-indole]-5'-carboxamide
Indication
Disease Entry ICD 11 Status REF
Liposarcoma 2B59 Phase 3 [1]
Cross-matching ID
PubChem CID
73297272
TTD Drug ID
DMPVDQ3

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Coagulation factor VIII (F8)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Drotrecogin alfa DM59JCN Cerebrovascular ischaemia 8B1Z Approved [3]
Factor 8 DMAB6PM Hemophilia 3B10.0 Approved [4]
Eloctate DMRCX8K Haemophilia A 3B10.0 Approved [5]
Efanesoctocog alfa DM2CKIJ Haemophilia A 3B10.0 Approved [6]
SK-NBP601 DMUY09W Hemophilia 3B10.0 Preregistration [7]
Recombinant von Willebrand factor/recombinant Factor VIII complex DM7JFDO Von willebrand disease 3B12 Phase 3 [8]
N8-GP DMY60DT Factor VIII deficiency 3B10 Phase 3 [9]
OBI-1 DMENDP6 Factor VIII deficiency 3B10 Phase 3 [10]
BAY 94-9027 DM09M3H Hemophilia 3B10.0 Phase 3 [11]
Plasma derived factor VIII PEGylated liposomal DM1RWMY Factor VIII deficiency 3B10 Phase 3 [4]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Coagulation factor VIII (F8) TT1290U FA8_HUMAN Not Available [2]

References

1 ClinicalTrials.gov (NCT04979442) A Randomized Multicenter Phase 3 Study of Milademetan Versus Trabectedin in Patients With Dedifferentiated Liposarcoma. U.S.National Institutes of Health.
2 A factor VIIIa-mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice. Blood. 2021 Oct 7;138(14):1258-1268.
3 Protein C in critical illness. Am J Health Syst Pharm. 2009 Jun 15;66(12):1089-96.
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2607).
5 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
6 Efanesoctocog alfa for hemophilia A: results from a phase 1 repeat-dose study. Blood Adv. 2022 Feb 22;6(4):1089-1094.
7 Clinical pipeline report, company report or official report of SK Chemicals.
8 6 Factor VIII Concentrates, Factor VIII/von Willebrand Factor Concentrates, Factor IX Concentrates, Activated Prothrombin Complex Concentrates. Transfus Med Hemother. 2009 December; 36(6): 409-418.
9 Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A. J Thromb Haemost. 2013 Apr;11(4):670-8.
10 Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A. Haemophilia. 2015 Mar;21(2):162-70.
11 Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A. J Thromb Haemost. 2014 Apr;12(4):488-96.